ArticleScientific reports2026
Molecular epidemiological characteristics of carbapenem-resistant Enterobacter cloacae complex.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study aimed to monitor the evolving antibiotic resistance patterns of carbapenem-resistant Enterobacter cloacae complex (CR-ECC) at the Fourth Hospital of Hebei Medical University, characterize the molecular epidemiology through resistance gene profiling and phylogenetic analysis, investigate virulence gene profiles, and establish an evidence-based framework for optimizing clinical antimicrobial therapy and infection control strategies. 32 CR-ECC isolates (2018-2022) underwent Vitek-based identification and susceptibility testing. Carbapenemase production was confirmed by mCIM, with whole-genome sequencing (Illumina) for MLST phylogeny (MEGA/iTOL). Plasmid replicons and resistance/virulence genes were analyzed using PlasmidFinder and RGI/BLAST respectively. CR-ECC emerged in 2020, reaching 32 cases by 2022 as the third most prevalent carbapenem-resistant Enterobacteriaceae. Isolates mainly from sputum (43.75%, 14/32) and blood (25.00%, 8/32), with 53.13% ICU origins. Universal resistance to piperacillin/tazobactam, ceftazidime, imipenem; full susceptibility to tigecycline/colistin. Molecular analysis identified 8 STs, predominantly ST171 (56.25%) carrying blaNDM-1/OXA-1. Plasmid analysis revealed Col(pHAD28)/IncC dominance with ST-specific distribution. Virulence genes showed near-universal fimA/csgD/entB (96.88%) and mrkD (90.63%). These findings highlight the therapeutic potential of tigecycline, colistin, and amikacin against CR-ECC, while emphasizing strain-specific aztreonam susceptibility in metallo-β-lactamase producers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.